← Back to Screener
Bicara Therapeutics Inc. Common Stock (BCAX)
Price$20.00
Momentum ScoreB
Favorite Metrics
Price vs S&P 500 (26W)-0.17%
Price vs S&P 500 (4W)-11.42%
VGM Score67.23
Market Capitalization$1.31B
All Metrics
Book Value / Share (Quarterly)$7.84
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-1.78
Price vs S&P 500 (YTD)10.68%
EPS (TTM)$-2.77
10-Day Avg Trading Volume0.49M
EPS Excl Extra (TTM)$-2.77
EPS (Annual)$-2.52
ROI (Annual)-34.36%
Cash / Share (Quarterly)$8.23
ROA (Last FY)-32.01%
EBITD / Share (TTM)$-3.09
Cash Flow / Share (Annual)$-1.89
P/B Ratio2.56x
P/B Ratio (Quarterly)2.53x
Net Income / Employee (Annual)$-1,339,300
Net Interest Coverage (TTM)-349.41x
ROA (TTM)-33.78%
EPS Incl Extra (Annual)$-2.52
Current Ratio (Annual)14.58x
Quick Ratio (Quarterly)13.72x
3-Month Avg Trading Volume0.53M
52-Week Price Return81.32%
Revenue / Employee (TTM)$0
52-Week High$24.25
EPS Excl Extra (Annual)$-2.52
26-Week Price Return7.76%
Quick Ratio (Annual)14.33x
13-Week Price Return8.11%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)13.85x
Enterprise Value$990.62M
Revenue / Employee (Annual)$0
Cash / Share (Annual)$7.33
3-Month Return Std Dev45.60%
Net Income / Employee (TTM)$-1,527,300
ROE (Last FY)-34.36%
EPS Basic Excl Extra (Annual)$-2.52
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-2.77
ROI (TTM)-35.89%
Revenue / Share (Annual)$0.00
Price vs S&P 500 (52W)56.96%
Year-to-Date Return18.84%
5-Day Price Return-3.01%
EPS Normalized (Annual)$-2.52
Month-to-Date Return-8.05%
EBITD / Share (Annual)$-2.84
EPS Basic Excl Extra (TTM)$-2.77
P/B Ratio (Annual)2.30x
Book Value / Share (Annual)$7.09
Price vs S&P 500 (13W)-0.15%
Beta1.02x
Revenue / Share (TTM)$0.00
ROE (TTM)-35.89%
52-Week Low$8.48
mGradeB
vgmGradeB
Show chart for
Earnings Surprise History
Q1 26-0.93est. -0.77
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
4.05
4.10
4.10
4.14
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
BCAXBicara Therapeutics Inc. Common Stock | — | — | B | $20.00 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
Bicara Therapeutics is a clinical-stage biopharmaceutical company developing bifunctional antibody therapies for solid tumors. Its lead program, ficerafusp alfa, combines an EGFR-directed monoclonal antibody with a TGF-beta binding domain, targeting two clinically validated oncology pathways.